Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Sep 27, 2021 (5 years ago)

Potassium Chloride Extended-Release Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Dissolution Specifications

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

Potassium Chloride Extended-Release Tablets, USP 10 mEq (750 mg), 500 Tablets, Rx Only, Manufactured by: Strides Shasun Limited, Bengaluru - 562106, India, Distributed by: Strides Pharma In., East Brunswick, NJ 08816, NDC 64380-861-07.

Affected NDC 64380-0861-07

Compare with the code on your package — it is the most precise check available.

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Potassium Chloride
NDC 64380-0861
750 mg/1 Tablet, Extended Release
Oral
Strides Pharma Science Limited Rx
Recalling firm
Strides Pharma Inc.
NDC code
64380-861-07
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0006-2022 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by Strides Pharma Inc.

All 2021 recalls

Other dissolution failure recalls from 2021

All dissolution failure recalls
Class III · Low risk

Fexofenadine HCl

Failed dissolution specifications

Terminated Dissolution failure Dr. Reddy's Laboratories, Inc. NDC 43598-823-31 D-0275-2022